CD4 and neoplasm: In early vaccine trials, when candidate tumor-relevant MHC-class II peptides were not yet identified, attempts to provide CD4+ T cell help were carried out by providing foreign proteins like keyhole limpet hemocyanin or tetanus toxoid.